A Randomized, Controlled Phase 3 Study of Cabozantinib (XL184) - Trial 2018-003354-24

Name: Clinical Trial 2018-003354-24
Creator: Exelixis, Inc.
Keywords: Hepatocellular carcinoma, clinical trial

Access comprehensive clinical trial information for 2018-003354-24 through Pure Global AI's free database. This phase not specified trial is sponsored by Exelixis, Inc. and is currently Ongoing. The study focuses on Hepatocellular carcinoma.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to EU Clinical Trials Register data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database

840K+ Trials

2018-003354-24

Ongoing

Trial Details

EU Clinical Trials Register • 2018-003354-24

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing

A Randomized, Controlled Phase 3 Study of Cabozantinib (XL184)

Study Focus

Disease/Condition

Hepatocellular carcinoma

Sponsor & Location

Primary Sponsor

Exelixis, Inc.

Funder

Exelixis, Inc

Timeline & Enrollment

Phase

N/A

Start Date

N/A

End Date

N/A

Primary Outcome

- Known Fibrolamellar carcinoma, sarcomatoid HCC or mixed hepatocellular cholangiocarcinoma.

ICD-10 Classifications

Malignant neoplasm: Hepatoblastoma

Malignant neoplasm: Liver cell carcinoma

Malignant neoplasm: Other specified carcinomas of liver

Malignant neoplasm: Liver, unspecified

Malignant neoplasm: Hepatic flexure

Data Source

Registry

EU Clinical Trials Register

Trial ID

2018-003354-24

Type

Non-Device Trial